{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2"},{"groupId":"OG001","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"720"},{"groupId":"OG001","value":"740"}],"units":"Participants"}],"description":"Cardiac events were defined as death from cardiac cause or severe congestive heart failure (New York Heart Association \\[NYHA\\] Class III or IV) with a decrease in left ventricular ejection fraction (LVEF) of 10 percentage points or more from baseline to an LVEF of \\< 50%. Other cardiac-related events (e.g., any symptomatic congestive heart failure \\[CHF\\] associated with a 10% drop in LVEF to \\< 50%; asymptomatic declines in LVEF requiring dose delay) were summarized as adjudicated by the Cardiac Review Committee. Percentages have been rounded off.","groups":[{"description":"Participants received trastuzumab, 6 mg/kg, IV, Q3W, as a maintenance dose for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG000","title":"Trastuzumab"},{"description":"Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG001","title":"Trastuzumab Emtansine"}],"paramType":"NUMBER","populationDescription":"SE population included all randomized participants who received any amount of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 126 months","title":"Percentage of Participants With Cardiac Events as Adjudicated by the Cardiac Review Committee","type":"SECONDARY","unitOfMeasure":"percentage of participants"}